CA2068333A1 - Composition et methode de protection du coeur pendant une reperfusion - Google Patents

Composition et methode de protection du coeur pendant une reperfusion

Info

Publication number
CA2068333A1
CA2068333A1 CA 2068333 CA2068333A CA2068333A1 CA 2068333 A1 CA2068333 A1 CA 2068333A1 CA 2068333 CA2068333 CA 2068333 CA 2068333 A CA2068333 A CA 2068333A CA 2068333 A1 CA2068333 A1 CA 2068333A1
Authority
CA
Canada
Prior art keywords
alanine
heart
effective amount
glutamate
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2068333
Other languages
English (en)
Inventor
Austin L. Shug
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2068333A1 publication Critical patent/CA2068333A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA 2068333 1990-09-10 1991-09-09 Composition et methode de protection du coeur pendant une reperfusion Abandoned CA2068333A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58012790A 1990-09-10 1990-09-10
US580,127 1990-09-10

Publications (1)

Publication Number Publication Date
CA2068333A1 true CA2068333A1 (fr) 1992-03-11

Family

ID=24319829

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2068333 Abandoned CA2068333A1 (fr) 1990-09-10 1991-09-09 Composition et methode de protection du coeur pendant une reperfusion

Country Status (4)

Country Link
EP (1) EP0509066A4 (fr)
AU (1) AU8513191A (fr)
CA (1) CA2068333A1 (fr)
WO (1) WO1992004023A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656608B1 (en) * 1995-02-23 2000-09-26 Novartis Nutrition Ltd Amino acid compositions and methods of treatment using same
GB9512100D0 (en) * 1995-06-14 1995-08-09 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
JP2002514184A (ja) 1996-09-27 2002-05-14 ギルフォード ファーマスーティカルズ インコーポレイテッド Ｎａａｌａｄアーゼ組成物ならびに動物におけるグルタメート異常を治療する方法および神経活性をもたらす方法
EP1475090A4 (fr) * 2002-02-14 2007-08-08 Ajinomoto Kk Medicaments pour maladies mitochondriales
DE10222561B4 (de) * 2002-05-17 2009-12-10 Dr. Franz Köhler Chemie GmbH Protektive Lösung zur Verhinderung von Ischämieschäden
US20090035383A1 (en) * 2005-08-19 2009-02-05 Shigeo Ohta Scavenger of in vivo harmful reactive oxygen species and/or free radicals

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2372626A1 (fr) * 1976-12-02 1978-06-30 Sertog Compositions therapeutiques a base d'un extrait de plantes et d'amino-acides
US4780475A (en) * 1986-02-03 1988-10-25 Cerra Frank B Preparation for the prevention of catabolism
SE8704217D0 (sv) * 1987-10-29 1987-10-29 Vinnars Erik Ab Aminosyrakomposition for parenteral neringstillforsel
JPH01216924A (ja) * 1988-02-24 1989-08-30 Ajinomoto Co Inc 肝障害治療剤

Also Published As

Publication number Publication date
WO1992004023A1 (fr) 1992-03-19
EP0509066A1 (fr) 1992-10-21
AU8513191A (en) 1992-03-30
EP0509066A4 (en) 1992-11-25

Similar Documents

Publication Publication Date Title
Preedy et al. The effects of 6 hours of hypoxia on protein synthesis in rat tissues in vivo and in vitro
US5208249A (en) Method for stimulating intracellular synthesis of glutathione using esters of L-2-oxothiazolidine-4-carboxylate
Mueller et al. Effect of dopamine on hemodynamics and myocardial metabolism in shock following acute myocardial infarction in man.
CA2068333A1 (fr) Composition et methode de protection du coeur pendant une reperfusion
US8350077B2 (en) Amides of creatine, method of their preparation, and remedy possessing a neuroprotective activity
US6482853B1 (en) Lactate thiolester for cardiac energy resuscitation and prevention of reperfusion injury and use as an energy supplement during exercise and recovery
US5631234A (en) Method for treating ischemia-reperfusion tissue injury
Ebmeyer et al. Strain specific differences in a cardio-pulmonary resuscitation rat model
Hopson et al. Allopurinol improves myocardial reperfusion injury in a xanthine oxidase-free model.
US4148920A (en) Therapeutic L- and DL- phenylglycines to treat diseases or disorders of reduced blood flow or oxygen availability
EA001099B1 (ru) Инъекционное лекарственое средство "цитофлавин", обладающее цитопротекторным действием
RU2096034C1 (ru) Фармацевтическая композиция, индуцирующая биосинтез глутатиона, активность глутатионтрансферазы и оказывающая антитоксическое, радиопротекторное и антигипоксическое действие, и способы лечения, профилактики и защиты с ее использованием
Demeyere et al. Cardioprotective effects of carnitine in extensive aortocoronary bypass grafting: a double-blind, randomized, placebo-controlled clinical trial
Lang et al. Regional and global myocardial effects of intravenous and sublingual nitroglycerin treatment after experimental acute coronary occlusion
US4185116A (en) L- and DL- Phenylglycines to treat diseases or conditions attributable to reduced carbohydrate metabolism
CA2083609C (fr) Agent de prevention ou de traitement de lesions tissulaires, de l'arrythmie et de lesions pulmonaires causees par l'oxygene actif et des radicaux libres
US5610160A (en) Topical 5-fluorouracil prodrug composition and method
Lippel et al. Palmitoyl-CoA synthetase activity in isolated rat epididymal fat cells in the absence and presence of various lipolytic and anti-lipolytic compounds
Morita et al. Studies of hypoxemic/reoxygenation injury: Without aortic clamping: VIII. Counteraction of oxidant damage by exogenous glutamate and aspartate
Bolling et al. Amino acid substrate preloading and postischemic myocardial recovery
ONAYA et al. Altered responsiveness to thyrotropin in thyroid slices of Graves' disease preoperatively treated with excess iodide
Levett et al. Effects of dimethyl sulfoxide on systemic and cerebral hemodynamic variables in the ischemic canine myocardium
US4179520A (en) L- and DL-Phenylglycines to treat a disease or condition attributable to reduced blood flow
Kirsch et al. Medical management and innovations
US4179521A (en) L- and DL-Phenylglycines to treat diseases or conditions attributable to reduced carbohydrate metabolism

Legal Events

Date Code Title Description
FZDE Dead